409A and Section 102: A Guide for Israeli Startups

For the definition, current provider cost examples and the 12-month refresh rules, start with our main 409A valuation guide. This companion focuses on coordinating US option pricing with Israel’s Section 102.

Every Israeli startup that flips to a Delaware C-Corp — or opens one from day one — eventually hits the same question from its US law firm: "when did you last do a 409A?" Founders who came up through the Israeli system, where Section 102 and the ITA govern option pricing, often don't realize a 409A is a *separate* US-tax requirement that runs in parallel. Missing it doesn't just create a paperwork problem; it can turn every option grant into an immediate taxable event for the employee, with a 20% federal penalty on top.

This guide covers what a 409A valuation is, when Israeli founders actually need one, how it differs from Israel's local option-pricing rules, and how to run both regimes at the same time without conflicts.

What Section 409A Actually Is

Section 409A of the US Internal Revenue Code governs "nonqualified deferred compensation" — which, for our purposes, includes stock options granted at a discount to fair market value (FMV). To grant options that qualify as safe-harbor priced, the company must determine FMV using a reasonable valuation method, applied consistently, and refreshed at least every 12 months or after a material event.

The most defensible way to meet the safe harbor is an independent 409A appraisal — a written report from a qualified appraiser that determines the FMV of the common stock. The report is what the IRS looks at if a grant is ever challenged; without it, the burden shifts to the company to prove the price was fair, which is very hard to do after the fact.

Why an Israeli Startup Needs One

If your cap table is on a Delaware C-Corp — even if the entire team sits in Tel Aviv — and you grant options to anyone who is a US taxpayer (including Israeli founders on green cards, dual citizens, or US-resident employees at a US subsidiary), 409A applies to *those* grants. In practice, once you have a Delaware C-Corp on top, US counsel will insist on a 409A for the whole option pool because:

• The cap table is a single instrument; you can't price the same class of stock two ways.
• Future investors and acquirers will diligence 409A compliance across all grants.
• The moment the company adds a US-resident hire, it needs a defensible FMV in place *before* the grant date, not after.

The Real Consequences of Skipping It

For the option holder, a 409A violation is punishing:

• Immediate tax on the option's spread at vesting, even without exercise.
• 20% federal penalty tax on the includable amount.
• Additional interest for the delay between vesting and reporting.
• State-level penalties, most notoriously California's additional 5% surcharge.

For the company: withholding failures, corrections that reopen prior returns, and — in an acquisition — an indemnity claim from the buyer that comes straight out of the escrow. In every Israeli-startup M&A we've seen, 409A history is one of the first three items on the buyer's diligence list.

409A vs. Israel's Section 102 — Not the Same Instrument

Israeli founders often assume that if they're pricing options correctly under Section 102 (capital gains route, trustee, 24-month holding) they're covered. They aren't. The two regimes ask different questions:

You need to satisfy both. A grant to an Israeli employee sitting in Tel Aviv, holding options in the Delaware parent, is subject to Section 102 on the Israeli side and — because the underlying security is US-parent stock — should still be priced at 409A FMV to avoid inconsistency and to keep the cap table clean for later grants to US-taxpayer employees. The 409A FMV becomes the exercise price used across the board.

When to Get a 409A Done

The trigger events are non-negotiable:

1. Before the very first option grant on the Delaware C-Corp cap table.
2. After every priced round (Seed, A, B…) — a preferred-stock financing is a material event.
3. After a large SAFE conversion or convertible note conversion that meaningfully changes the cap table.
4. After a significant secondary transaction at a materially different price.
5. After a material business change — big new revenue, a major pivot, an M&A LOI, a large customer loss.
6. Every 12 months at minimum, even if nothing else happened.

Between triggers, the existing 409A remains "safe-harbor" — grants at that price are presumed reasonable unless the IRS shows the company knew the report was materially wrong.

What the Valuation Report Actually Contains

A defensible 409A report walks through:

• Enterprise value using an income approach (DCF on your projections), a market approach (comparable public companies and recent transactions), and, for very early stage, an asset-based cross-check.
• Equity allocation — how the enterprise value splits across preferred and common. For most venture-backed startups this is either an Option Pricing Model (OPM) or a Probability-Weighted Expected Return Method (PWERM), depending on how close you are to an exit.
• Discount for Lack of Marketability (DLOM) — typically 15–40% for private common stock, driven by time-to-liquidity, volatility, and dividend expectations.
• Concluded FMV per common share — the number that becomes your option strike price until the next event.

The gap between preferred and common (the "common discount") is usually the single most contested output. Early stage: common is often 10–25% of preferred. Series B and beyond, that gap compresses as an exit becomes more likely.

Typical Ranges by Stage

These are ranges, not targets — the actual number is driven by your specific facts.

The Israeli-Startup Playbook

Concretely, here's how we run this at Aleph Accounting for a typical Delaware-on-top Israeli startup:

1. Get the first 409A before any option paperwork. Not after board approval, not after promises to hires — before. A backdated grant with a later-dated 409A is one of the ugliest audit trails there is.

2. File Section 102 with the ITA in parallel. The plan filing, trustee appointment (IBI / ESOP Management & Trust / Altshuler), and 30-day notice have to be in place before Israeli grants vest under the capital gains route. Missing this collapses the tax route to ordinary income — a much worse outcome for the employee than a 409A miss.

3. Use the same strike price everywhere. The 409A FMV is the strike for US grants; it should also be the strike for the Israeli §102 grants on the same class of stock, to avoid an inconsistent-pricing story at diligence.

4. Refresh after every round, even small ones. A $2M SAFE at a $30M cap that converts materially changes the cap table. Don't wait for the next 12-month anniversary.

5. Keep a "grant checklist." For every grant: (a) valid 409A on file, (b) board or committee approval dated *after* the 409A, (c) grant notice signed, (d) if Israeli — trustee notice filed, (e) if US — 83(b) election filed within 30 days for restricted stock. Missing any one of these is the mistake we clean up most often.

Cost, Timeline, and Providers

• Cost: See the main 409A guide’s sourced provider pricing examples. Request a quote for your capital structure and refresh needs.
• Turnaround: 2–4 weeks for a first report; 1–2 weeks for subsequent refreshes if the appraiser already has your data.
• Validity: 12 months or until a material event.

We coordinate 409A appraisals for every Israeli-startup client the moment the Delaware C-Corp is stood up, and refresh on the round cadence. The cost is a rounding error compared to the tax risk on a single mispriced grant.

Common Mistakes We See

1. Assuming Israeli option pricing covers the US side. It doesn't. 409A is a separate US-tax question about US-corp stock.
2. Granting first, valuing later. The 409A must exist *before* the grant date. Post-hoc valuations don't retroactively cure a below-FMV grant.
3. Using a stale 409A after a priced round. A Series A closing at a $50M pre-money on Monday makes Friday's grants at the pre-round strike a 409A violation.
4. Skipping the 12-month refresh because "nothing changed." The safe harbor requires a refresh; skipping it forfeits it.
5. Inconsistent strike prices between US and Israeli grants on the same class — a red flag in every diligence process.
6. Missing the §102 filing in parallel with the 409A. Two regimes, both required, both easy to get wrong on their own.

When to Get Help

Get a free 409A report-fee estimate before discussing your option-grant budget. This estimates report fees, not share value.

If you have a Delaware C-Corp on the cap table and you've ever thought "we'll do the 409A when we grant options" — you're already late. Get the appraisal engaged the same week the Delaware entity is stood up, and file §102 with the ITA in parallel. The forms are boilerplate; the sequencing is what breaks companies at diligence.